Etoposide phosphate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1996
- First approval year
- 1996
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Etoposide phosphate
- Molecular weight
- 668.54
- Structure (SMILES)
- COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O
- etopophos
- Etopophos
- etopophos preservative free
- Etopophos preservative free
- 4 demethylepipodophyllotoxin 9 4 6 o r ethylidene beta d glucopyranoside 4 dihydrogen phosphate
- 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE), 4'-(DIHYDROGEN PHOSPHATE)
- bmy 40481
- BMY 40481
- BMY-40481
- etopophos
- etoposide phosphate
- Etoposide phosphate
- ETOPOSIDE PHOSPHATE [MART.]
- ETOPOSIDE PHOSPHATE [MI]
- ETOPOSIDE PHOSPHATE [ORANGE BOOK]
- ETOPOSIDE PHOSPHATE [USAN]
- ETOPOSIDE PHOSPHATE [USP MONOGRAPH]
- ETOPOSIDE PHOSPHATE [USP-RS]
- ETOPOSIDE PHOSPHATE [VANDF]
- Etoposide phosphate [WHO-DD]
- etoposide phosphate mart
- etoposide phosphate mi
- etoposide phosphate orange book
- etoposide phosphate usan
- etoposide phosphate usp monograph
- etoposide phosphate usp rs
- etoposide phosphate vandf
- etoposide phosphate who dd
- furo 3 4 6 7 naphtho 2 3 d 1 3 dioxol 6 5ah one 5 3 5 dimethoxy 4 phosphonooxy phenyl 9 4 6 o ethylidene beta d glucopyranosyl oxy 5 8 8a 9 tetrahydro 5r 5 alpha 5a beta 8a alpha 9 beta r
And 8 more, listed on the interactive page.
- CAS registry numbers
- 117091-64-2
- ChEMBL ID
- CHEMBL1200645
- InChIKey
- LIQODXNTTZAGID-OCBXBXKTSA-N
- PubChem compound IDs
- 6918092
- RxNorm IDs (RxCUI)
- 24614
- FDA ingredient codes (UNII)
- 528XYJ8L1N
- Applicant
- CHEPLAPHARM
- Approval date
- 17 May 1996
- Application number
- NDA020457
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
- Protein identifier
- P11388
Open Targets mechanisms
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TOP2A
- Protein identifier
- P11388
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000094
- Subject identifier
- D015456
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Neoplasms, Plasma Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000200
- Subject identifier
- D054219
- Condition
- Leukemia, Biphenotypic, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000209
- Subject identifier
- D015456
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Burkitt Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000309
- Subject identifier
- D002051
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Ganglioneuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000502
- Subject identifier
- D018305
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neuroblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Multiple Myeloma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Oligodendroglioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002501
- Subject identifier
- D009837
- Condition
- Rhabdomyosarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002918
- Subject identifier
- D012208
- Condition
- Medulloblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002939
- Subject identifier
- D008527
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Central Nervous System Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000158
- Subject identifier
- D016543
- Condition
- Lymphoma, AIDS-Related
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001365
- Subject identifier
- D016483
- Condition
- Lymphoma, Mantle-Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001469
- Subject identifier
- D020522
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0000873
- Subject identifier
- D054198
- Condition
- Peritoneal Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002087
- Subject identifier
- D010534
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
And 6 more, listed on the interactive page.
- Condition identifier
- EFO_0000183
- Condition identifier
- EFO_0000220
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001657
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002158
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002571
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002598
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004952
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004963
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005040
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005072
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005140
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005212
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005440
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005563
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007243
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008433
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0012817
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015459
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015540
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0015686
- Highest recorded phase
- 1
And 14 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 53
- Reporting signal score
- 51.9593
- Event
- acute myeloid leukaemia
- Reports
- 371
- Reporting signal score
- 778.155
- Event
- acute myelomonocytic leukaemia
- Reports
- 5
- Reporting signal score
- 24.4615
- Event
- anaemia
- Reports
- 1,057
- Reporting signal score
- 459.888
- Event
- antithrombin iii deficiency
- Reports
- 4
- Reporting signal score
- 21.8527
- Event
- aplasia
- Reports
- 10
- Reporting signal score
- 31.5802
- Event
- bone marrow failure
- Reports
- 642
- Reporting signal score
- 1,067.73
- Event
- caecitis
- Reports
- 5
- Reporting signal score
- 19.9007
- Event
- device related thrombosis
- Reports
- 6
- Reporting signal score
- 22.0465
- Event
- diffuse large b-cell lymphoma recurrent
- Reports
- 123
- Reporting signal score
- 324.176
- Event
- dilatation intrahepatic duct acquired
- Reports
- 28
- Reporting signal score
- 173.968
- Event
- disease progression
- Reports
- 694
- Reporting signal score
- 504.883
- Event
- encephalopathy
- Reports
- 26
- Reporting signal score
- 46.145
- Event
- febrile bone marrow aplasia
- Reports
- 189
- Reporting signal score
- 375.079
- Event
- febrile neutropenia
- Reports
- 2,913
- Reporting signal score
- 6,586.53
- Event
- haematotoxicity
- Reports
- 386
- Reporting signal score
- 801.865
- Event
- hepatotoxicity
- Reports
- 31
- Reporting signal score
- 66.576
- Event
- hypertriglyceridaemia
- Reports
- 15
- Reporting signal score
- 36.669
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 313.013
- Event
- leukopenia
- Reports
- 592
- Reporting signal score
- 530.196
- Event
- liver function test abnormal
- Reports
- 18
- Reporting signal score
- 20.2976
- Event
- malignant neoplasm progression
- Reports
- 518
- Reporting signal score
- 412.048
- Event
- mucosal inflammation
- Reports
- 919
- Reporting signal score
- 1,731.75
- Event
- myelodysplastic syndrome
- Reports
- 437
- Reporting signal score
- 856.654
- Event
- myelosuppression
- Reports
- 304
- Reporting signal score
- 517.891
And 15 more, listed on the interactive page.
- NCT00001563
- NCT00002880
- NCT00006669
- NCT00053768
- NCT00060385
- NCT00069238
- NCT00074178
- NCT00974792
- NCT00983944
- NCT01132807
- NCT02106988
- NCT04759586
- NCT00003064
- NCT00005780
- NCT00114738
- NCT00005792
- NCT02356159
- NCT00011921
- NCT00433498
- NCT01160731
- NCT00017368
- NCT00410631
- NCT00417053
- NCT01175356
- NCT03126916
And 28 more, listed on the interactive page.
- Dose
- 50-100 mg/m2 per day
- Route
- Intravenous
- How often
- Days 1-5 of each 21-day or 28-day cycle, or days 1, 3, and 5 of each cycle
Conditions of use
- Do not give by bolus injection
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 4
- Polar surface area
- 207.36
- Calculated partition coefficient (ALogP)
- 1.1
- Calculated partition coefficient (XLogP)
- -0.7
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 7
- Heavy atoms
- 46
- Molecular formula
- C29H33O16P
- Monoisotopic mass
- 668.15062196
- Natural product
- Yes
- 61269-410
- Recorded assays
- 32
- Active assays
- 4
Active assay types
- Confirmatory
- Antineoplastic Agents
Related records
Trials (1,431)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
- A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
- A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
- A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
- A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
- A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
In development for (30)
- Acute lymphoblastic leukemia Phase 3
- Acute myeloid leukemia Phase 1
- Anaplastic oligodendroglioma Phase 1
- B-cell acute lymphoblastic leukemia Phase 2
- Burkitt lymphoma Phase 2
- Carcinoma Phase 3
- Central nervous system neoplasm Phase 3
- Diffuse large B-cell lymphoma Phase 3
- Fallopian tube cancer Phase 1
- Ganglioneuroblastoma Phase 3
- Hemophagocytic syndrome Phase 2
- Hodgkins lymphoma Phase 3
- Leukemia Phase 2
- Lung cancer Phase 3
- Lymphoblastic lymphoma Phase 3
- Lymphoma Phase 3
- Malignant glioma Phase 2
- Mantle cell lymphoma Phase 2
- Medulloblastoma Phase 2
- Mixed glioma Phase 2
Targets (1)
- TOP2A DNA topoisomerase II alpha inhibitor